Pluri Inc. (PLUR) EBITDA
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$6.54M; Depreciation and amortization (m).
- 2025-12-31: Basis Reported; EBITDA (m); Operating income -$6.51M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$6.35M; Depreciation and amortization (m).
- 2025-03-31: Basis Reported; EBITDA (m); Operating income -$5.40M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | Reported | (m) | -$6.54M | (m) | (m) | (m) | $44.00K* | -$4.51M* | (m) | $3.96M | (m) | -$8.00K |
| 2025-12-31 | Reported | (m) | -$6.51M | (m) | (m) | (m) | $447.00K* | -$5.21M* | (m) | $3.83M | (m) | -$8.00K |
| 2025-09-30 | Reported | (m) | -$6.35M | (m) | (m) | (m) | $116.00K | -$5.43M | (m) | $3.93M | (m) | -$8.00K |
| 2025-03-31 | Reported | (m) | -$5.40M | (m) | (m) | (m) | $577.00K* | -$4.30M* | (m) | $3.04M | (m) | (m) |
| 2024-12-31 | Reported | (m) | -$4.96M | (m) | (m) | (m) | $112.00K* | -$4.63M* | (m) | $2.92M | (m) | (m) |
| 2024-09-30 | Reported | (m) | -$5.20M | (m) | (m) | (m) | $208.00K | -$4.06M | (m) | $2.89M | (m) | (m) |
| 2024-03-31 | Reported | (m) | -$5.53M | (m) | (m) | (m) | $89.00K* | -$4.20M* | (m) | $3.09M | (m) | (m) |
| 2023-12-31 | Reported | (m) | -$5.21M | (m) | (m) | (m) | $121.00K* | -$3.65M* | (m) | $2.96M | (m) | (m) |
| 2023-09-30 | Reported | (m) | -$5.38M | (m) | (m) | (m) | $103.00K | -$5.86M | (m) | $2.99M | (m) | (m) |
| 2023-03-31 | Reported | (m) | -$7.10M | (m) | (m) | (m) | $24.00K* | -$6.07M* | (m) | $4.17M | (m) | (m) |
| 2022-12-31 | Reported | (m) | -$6.68M | (m) | (m) | (m) | $68.00K* | -$6.28M* | (m) | $3.79M | (m) | (m) |
| 2022-09-30 | Reported | (m) | -$6.92M | (m) | (m) | (m) | $73.00K | -$7.61M | (m) | $4.50M | (m) | (m) |
| 2022-03-31 | Reported | (m) | -$10.47M | (m) | (m) | (m) | $37.00K* | -$9.42M* | (m) | $6.27M | (m) | (m) |
| 2021-12-31 | Reported | (m) | -$10.79M | (m) | (m) | (m) | $29.00K* | -$9.86M* | (m) | $6.54M | (m) | (m) |
| 2021-09-30 | Reported | (m) | -$11.44M | (m) | (m) | (m) | $15.00K | -$8.79M | (m) | $6.39M | (m) | (m) |
| 2021-03-31 | Reported | (m) | -$14.22M | (m) | (m) | (m) | $124.00K* | -$7.33M* | (m) | $7.82M | (m) | (m) |
| 2020-12-31 | Reported | (m) | -$13.07M | (m) | (m) | (m) | $130.00K* | -$7.84M* | (m) | $8.00M | (m) | (m) |
| 2020-09-30 | Reported | (m) | -$8.74M | (m) | (m) | (m) | $77.00K | -$6.14M | (m) | $6.20M | (m) | (m) |
| 2020-03-31 | Reported | (m) | -$7.40M | (m) | (m) | (m) | $29.00K* | -$6.50M* | (m) | $5.74M | $1.68M | (m) |
| 2019-12-31 | Reported | (m) | -$6.37M | (m) | (m) | (m) | $74.00K* | -$6.30M* | (m) | $5.57M | (m) | (m) |
| 2019-09-30 | Reported | (m) | -$7.20M | (m) | (m) | (m) | $54.00K | -$7.24M | (m) | $5.83M | (m) | (m) |
| 2019-03-31 | Reported | (m) | -$10.30M | (m) | (m) | (m) | $24.00K* | -$6.01M* | (m) | $8.42M | $2.47M | (m) |
| 2018-12-31 | Reported | (m) | -$8.33M | (m) | (m) | (m) | $16.00K* | -$8.26M* | (m) | $7.43M | (m) | (m) |
| 2018-09-30 | Reported | (m) | -$8.97M | (m) | (m) | (m) | $177.00K | -$8.51M | (m) | $7.76M | (m) | (m) |
| 2018-03-31 | Reported | (m) | -$9.05M | (m) | (m) | (m) | $34.00K* | -$5.58M* | (m) | $7.48M | (m) | (m) |
| 2017-12-31 | Reported | (m) | -$8.47M | (m) | (m) | (m) | $37.00K* | -$4.83M* | (m) | $6.26M | (m) | (m) |
| 2017-09-30 | Reported | (m) | -$7.44M | (m) | (m) | (m) | $148.00K | -$5.19M | (m) | $5.19M | (m) | (m) |
| 2017-03-31 | Reported | (m) | -$8.22M | (m) | (m) | (m) | $87.00K* | -$5.52M* | (m) | $6.58M | (m) | (m) |
| 2016-12-31 | Reported | (m) | -$6.65M | (m) | (m) | (m) | $128.00K* | -$5.78M* | (m) | $5.48M | (m) | (m) |
| 2016-09-30 | Reported | (m) | -$6.56M | (m) | (m) | (m) | $145.00K | -$3.92M | (m) | $6.03M | (m) | (m) |
| 2016-03-31 | Reported | (m) | -$7.39M | (m) | (m) | (m) | $64.00K* | (m) | (m) | $5.80M | (m) | (m) |
| 2015-12-31 | Reported | (m) | -$4.23M | (m) | (m) | (m) | $365.00K* | (m) | (m) | $5.57M | (m) | (m) |
| 2015-09-30 | Reported | (m) | -$5.52M | (m) | (m) | (m) | $1.11M | (m) | (m) | $5.06M | (m) | (m) |
| 2015-03-31 | Reported | (m) | -$7.53M | (m) | (m) | (m) | $86.00K* | (m) | (m) | $6.18M | (m) | (m) |
| 2014-12-31 | Reported | (m) | -$6.30M | (m) | (m) | (m) | $281.00K* | (m) | (m) | $5.38M | (m) | (m) |
| 2014-09-30 | Reported | (m) | -$5.62M | (m) | (m) | (m) | $271.00K | (m) | (m) | $5.74M | (m) | (m) |
| 2014-03-31 | Reported | (m) | -$9.29M | (m) | (m) | (m) | $267.00K* | (m) | (m) | $6.88M | (m) | (m) |
| 2013-12-31 | Reported | (m) | -$6.99M | (m) | (m) | (m) | $707.00K* | (m) | (m) | $6.11M | (m) | (m) |
| 2013-09-30 | Reported | (m) | -$4.86M | (m) | (m) | (m) | $462.00K | -$5.09M | (m) | $5.50M | (m) | (m) |
| 2013-03-31 | Reported | (m) | -$5.93M | (m) | (m) | (m) | -$91.00K* | -$11.87M* | (m) | $4.96M | (m) | (m) |
| 2012-12-31 | Reported | (m) | -$4.88M | (m) | (m) | (m) | $1.36M* | $3.52M* | (m) | $4.15M | (m) | (m) |
| 2012-09-30 | Reported | (m) | -$4.19M | (m) | (m) | (m) | $1.98M | -$3.52M | (m) | $3.75M | (m) | (m) |
| 2012-06-30 | Reported | (m) | -$3.97M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | Reported | (m) | -$4.61M | (m) | (m) | (m) | $1.31M* | -$2.35M* | (m) | $3.42M | (m) | (m) |
| 2011-12-31 | Reported | (m) | -$2.12K | (m) | (m) | (m) | -$178.00K* | -$3.46M* | (m) | $2.97K | (m) | (m) |
| 2011-09-30 | Reported | (m) | -$4.33M | (m) | (m) | (m) | $179.00K | $3.46M | (m) | $2.86M | (m) | (m) |
| 2011-06-30 | Reported | (m) | -$3.84M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | Reported | (m) | -$2.70M | (m) | (m) | (m) | $112.00K* | -$1.38M* | (m) | $2.15M | (m) | (m) |
| 2010-12-31 | Reported | (m) | -$2.82M | (m) | (m) | (m) | $134.00K* | -$1.53M* | (m) | $2.19M | (m) | (m) |
| 2010-09-30 | Reported | (m) | -$1.75M | (m) | (m) | (m) | $426.00K | -$688.00K | (m) | $1.50M | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | -$24.43M* | -$24.94M | $511.00K | (m) | (m) | $633.00K | -$19.59M | (m) | $15.09M | (m) | -$25.00K |
| 2025-06-30 | Reported | -$21.86M* | -$22.18M | $316.00K | (m) | (m) | $1.62M | -$18.21M | (m) | $12.85M | (m) | -$5.00K |
| 2024-06-30 | Reported | (m) | -$22.16M | (m) | (m) | (m) | $323.00K | -$18.02M | (m) | $12.45M | (m) | (m) |
| 2023-06-30 | Reported | (m) | -$27.25M | (m) | (m) | (m) | $262.00K | -$22.86M | (m) | $15.74M | (m) | (m) |
| 2022-06-30 | Reported | (m) | -$41.59M | (m) | (m) | (m) | $280.00K | -$36.50M | (m) | $24.61M | (m) | (m) |
| 2021-06-30 | Reported | (m) | -$50.62M | (m) | (m) | (m) | $373.00K | -$30.91M | (m) | $30.53M | (m) | (m) |
| 2020-06-30 | Reported | (m) | -$29.48M | (m) | (m) | (m) | $270.00K | -$26.37M | (m) | $23.10M | (m) | (m) |
| 2019-06-30 | Reported | (m) | -$35.53M | (m) | (m) | (m) | $239.00K | -$29.45M | (m) | $29.88M | (m) | (m) |
| 2018-06-30 | Reported | (m) | -$33.73M | (m) | (m) | (m) | $342.00K | -$21.38M | (m) | $26.37M | (m) | (m) |
| 2017-06-30 | Reported | (m) | -$28.02M | (m) | (m) | (m) | $378.00K | -$21.61M | (m) | $24.00M | (m) | (m) |
| 2016-06-30 | Reported | (m) | -$23.32M | (m) | (m) | (m) | $1.75M | -$18.52M | (m) | $22.86M | (m) | (m) |
| 2015-06-30 | Reported | (m) | -$25.27M | (m) | (m) | (m) | $831.00K | -$20.61M | (m) | $23.42M | (m) | (m) |
| 2014-06-30 | Reported | (m) | -$27.85M | (m) | (m) | (m) | $1.57M | (m) | (m) | $24.94M | (m) | (m) |
| 2013-06-30 | Reported | (m) | -$22.22M | (m) | (m) | (m) | $4.31M | -$16.89M | (m) | $19.91M | (m) | (m) |
| 2013-03-31 | Rolling | (m) | -$18.98M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | Rolling | (m) | -$17.66M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-09-30 | Rolling | (m) | -$12.77M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | Reported | (m) | -$15.03M | (m) | (m) | (m) | $1.48M | -$3.27M | (m) | $12.69M | (m) | (m) |
| 2012-06-30 | Rolling | (m) | -$12.92M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | Rolling | (m) | -$12.78M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | Rolling | (m) | -$10.87M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-09-30 | Rolling | (m) | -$13.69M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | Reported | (m) | -$11.11M | (m) | (m) | (m) | $962.00K | -$5.75M | (m) | $8.31M | (m) | (m) |
| 2011-06-30 | Rolling | (m) | -$11.11M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | Reported | (m) | -$7.44M | (m) | (m) | (m) | $389.00K | -$5.41M | (m) | $6.12M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B |